On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Ending the Need to Light-Up

  • Lexaria is ahead of the game in the expected second flow of investment capital in “plant-to-bloodstream” companies
  • Company’s DehydraTECH™ technology has the potential to revolutionize nicotine use, eliminating the major cause of related deaths by shifting demand away from smoking cigarettes
  • DehydraTECH™ makes it possible to experience most of the positives associated with inhalation while eliminating the negatives, helping to make lighting up a thing of the past

Within the cannabis industry, the initial flow of investment capital has been toward ‘seed-to-plant’ companies. As the next stage of investment is expected to be ‘plant-to-bloodstream’, companies such as Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) are positioned ahead of the game. LXRP’s revolutionary DehydraTECH™ technology disrupts the traditional ways that cannabinoids enter the bloodstream, including through inhalation, under the tongue and through edibles. Each of these three historic methods have their own challenges.

First, inhalation is unhealthy, allowing toxins from the combustion process to enter the bloodstream. People die every day from smoking cigarettes, and no rational person can argue in favor of smoking. Second, edible producers often mask the bitter taste of hemp oils and cannabis oils through the use of excessive sugar or unwanted artificial sweeteners. Additionally, the active ingredients are broken down by the liver, largely destroyed by stomach acid and unable to significantly cross the intestinal wall. Lexaria’s patented technology, DehydraTECH™, improves the effectiveness of the active ingredients and addresses these common problems. DehydraTECH™ reduces the bitter flavor, making sweeteners unnecessary. It also protects the active ingredients during stomach transit and amplifies intestinal absorption by up to 10x, as compared to edible forms that have not been technically enhanced. In addition, the tech has the ability to bypass first-pass liver metabolism, greatly improving the rapidity with which the active ingredient can take effect.

This revolutionary edible technology extends beyond cannabinoids, as the company continues to evaluate its potential use for nicotine delivery and a smoke-free future. According to the Centers for Disease Control and Prevention, approximately six million deaths per year globally are attributed primarily to the act of smoking nicotine products. Nicotine, however, is not primarily responsible. According to the U.K. National Institute for Health and Care Excellence (NICE), “The harm associated with cigarette smoking is almost entirely caused by the toxins and carcinogens found in tobacco smoke – not the nicotine” (http://nnw.fm/TN8f0). Lexaria believes that DehydraTECH™ has the potential to revolutionize nicotine use by allowing users to avoid the dangerous chemicals associated with the normal inhalation means of getting nicotine, effectively eliminating the major cause of related deaths by shifting demand away from smoking cigarettes and toward common food and consumer products. Early animal testing of DehydraTECH™ has shown dramatically faster delivery of nicotine to the bloodstream than controls.

Although inhalation is an effective delivery mechanism – much more so than non-enhanced edible ingestion – it is dangerous. The toxins released during combustion are harmful and can potentially kill the user. Edible ingestion eliminates the toxins caused by lighting up. While inhalation is fast, traditionally, ingestion has not been. However, the use of DehydraTECH™ speeds things up to make edible absorption roughly as fast as inhalation, allowing for non-deadly yet effective forms of absorption. This revolutionary technology makes it possible to experience most of the positives of inhalation while eliminating the negatives and making lighting up a thing of the past.

Lexaria Bioscience Corporation was recently added to the CSE 25 stock index, reflecting its recent growth to become one of the 25 largest-capitalized companies on the Canadian Securities Exchange (http://nnw.fm/6Xc7T).

In addition, Horizons Marijuana Life Sciences Index ETF recently added Lexaria as one of its core stock holdings, buying Lexaria’s common stock on the open market (http://nnw.fm/GM9hY). Lexaria Bioscience Corp. is clearly receiving more widespread recognition as a sector leader than it ever has in the past.

For more information, visit the company’s website at www.LexariaEnergy.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Archives

Select A Month

Contact us: 212.418.1217